ABSTRACT
Background In July 2014, Kenya introduced the Rotarix® vaccine into its national immunization program. The impact of this vaccination programme on the local epidemiology of enteropathogens is unclear.
Methods The TaqMan Array Card (TAC) was used for screening for 28 different enteropathogens in 718 stools from children less than 13 years of age who presented with diarrhea and were admitted to Kilifi County Hospital, coastal Kenya, in 2013 (before vaccine introduction) and in 2016-2018 (after vaccine introduction). The differences between pre- and post-Rotarix® vaccination periods were examined using univariate and multivariable logistic regressions.
Results In 665 specimens (92.6%), one or more enteropathogens were detected, while in 323 specimens (48.6%), three or more enteropathogens were detected. There was a significant increase in the proportion of samples containing enteroaggregative Escherichia coli (35.7% vs 45.3%, p=0.014), cytomegalovirus (4.2% vs 9.9%, p=0.008), Vibrio cholerae (0.0% vs 2.3%, p=0.019), Strongyloides species (0.8% vs 3.6%, p=0.048) and Dientamoeba fragilis (2.1% vs 7.8%, p=0.004) post-vaccine introduction. Sapovirus detection decreased significantly (7.6% vs 4.0%, p=0.030) post-vaccine introduction. The proportion of samples that tested positive for rotavirus group A did not statistically differ between the pre- and post-vaccine periods (27.4% vs. 23.5%, p=0.253).
Conclusions In this setting, the burden of childhood enteropathogen infection was high both pre- and post-rotavirus vaccination introduction, with some specific changes in the burden of enteropathogens in hospitalized children after rotavirus vaccination introduction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Cambridge-Africa ALBORADA Research Fund. Dr Charles Agoti was supported by the Initiative to Develop African Research Leaders (IDeAL) through the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa Development Planning and Coordinating Agency (NEPAD Agency). Dr Lydia Drumright was supported by the following funding sources during this study (Medical Research Council (award # MR/S013164/1)), the Alan Turing Institute through a Research Fellowship, the National Institutes for Health Research (award # CDF-2011-04-017) and the Cambridge Biomedical Research Center, the Economic and Social Science Research Council (award # AH/R001952/1), and an Isaac Newton/Wellcome Trust ISSF award to understand gastrointestinal infection epidemiology through use of this TAC. The views expressed in this report are those of the authors and not necessarily those of AAS, NEPAD Agency, The Wellcome, the UK government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Before sample collection, informed written consent was gained from each child parent/guardian. The Scientific and Ethics Review Unit (SERU) at Kenya Medical Research Institute, Nairobi, approved the study protocol (Protocol #3624).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimers The views expressed in this article are solely those of the authors and not of the funders or affiliated institutions.
Source (s) of support This study was supported by the Cambridge-Africa ALBORADA Research Fund.
Disclosure of relationships and activities
Data Availability
The data described in this manuscript can be accessed by submitting a request form to our Data Governance Committee (http://kemri-wellcome.org/about-us/#ChildVerticalTab_15).